Oncology Medical News about malignant melanoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Autophagy in cutaneous malignant melanoma
Journal of Cutaneous Pathology, 07/16/09

Lazova R et al. - In a study to detect whether malignant melanoma cells display levels of autophagy, the results suggest that therapies inhibiting autophagy may be effective for treatment of malignant melanoma by depriving cells of an important energy source.

Methods

In a panel of 12 cases of cutaneous malignant melanoma of the superficial spreading type, cells in florid melanoma in situ (MIS) and invasive cells in the dermis were examined.

Results

In a panel of 12 cases of cutaneous malignant melanoma of the superficial spreading type, cells in florid melanoma in situ (MIS) and invasive cells in the dermis appeared to be undergoing autophagy.
Autophagosomes were detected through immunohistochemistry using the marker LC3B (microtubule-associated light chain 3B), and by electron microscopy.
Some autophagosomes contained melanized melanosomes, accounting for the phenomenon of 'coarse melanin' in malignant melanoma.
Autophagosomes contained the Golgi 58k protein, a structural component of the Golgi apparatus, and β1, 6-branched oligosaccharides, indicating that at least some of the autophagosomal proteins were glycosylated with these structures.
Findings suggest that autophagy could be a constitutive metabolic state for invasive and metastatic melanoma cells.
A similar phenotype was also expressed by tumor-associated melanophages.

<< Previous
Measuring therapeutic efficacy in the changing paradigm of...

Next >>
Risk of death from prostate cancer after brachytherapy alone or...

Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma
Cancer, 10/30/09 Relevance Score: 69%

Analysis of Globule Types in Malignant Melanoma
Archives of Dermatology, 11/17/09 Relevance Score: 68%

Ground-glass nodules found in two patients with malignant melanomas: different growth rate and different histology
Clinical Imaging, 11/17/09 Relevance Score: 68%

Unusual variants of malignant melanoma
Clinics in Dermatology, 11/06/09 Relevance Score: 67%

Patterns of GRP78 and MTJ1 expression in primary cutaneous malignant melanoma
Modern Pathology, 10/23/09 Relevance Score: 67%